Eisai Drug That Failed For Sepsis Could Be New Way To Treat Evolving Flu
This article was originally published in PharmAsia News
An Eisai drug that failed testing for treating another disease may be able to provide a new way of treating influenza, including the new viruses, by acting on the patient instead of the virus.
You may also be interested in...
Partnering with AstraZeneca, the Oxford team has opened up a clear lead in the race to enrol thousands of patients for late-stage safety and efficacy trials – but cannot make guarantees of when results might be ready.
Pharma’s latest partnerships focus on Duchenne muscular dystrophy with Precision Biosciences, protein degradation with Seed. Bristol and Schrodinger team in computational drug discovery.
In the second segment of a two-part article on transparency provisions for the new EU clinical trial portal, a senior Merck executive explains how the company will ensure that commercially sensitive information and personal data in its clinical trial applications are not made public.